At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 408 enrolled
Drug / intervention
ADL5859 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of ADL5859 and ADL5747 in Subjects With Moderate to Severe Pain Due to Osteoarthritis of the Knee
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Sep 18, 2009·Updated Aug 14, 2015
In Brief
A Phase 2 clinical trial evaluating ADL5859, ADL5747, and 2 other interventions for Osteoarthritis of the Knee. Completed, enrolled 408 participants across 11 sites.
Detailed Summary
The purpose of this study is to determine the efficacy of ADL5859 versus placebo and ADL5747 versus placebo in relieving pain in participants with osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartOct 2009
Primary CompletionApr 2010
Study CompletionJun 2010
TodayJul 2026
First PostedSep 18, 2009
Enrollment StartOct 1, 2009
Primary CompletionApr 1, 2010
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.8 years ago
Interventions
ADL5859drug
ADL5747drug
Oxycodone CRdrug
Placebodrug